_1777294237270_124456903.png&w=48&q=75){kind=small}
FDA approves Zinbexos for multiple myeloma
The Saudi Food and Drug Authority has approved the drug "Epidromid" (Zinebexos), an innovative treatment for multiple myeloma, making it the first product of its kind to be approved in the Kingdom for this disease. The medication is used as an adjunct alongside other drugs to alleviate symptoms of the tumor and strengthen the immune response. It targets tumor cells in a way that prevents their proliferation and helps improve treatment outcomes. The approval was based on clinical research demonstrating significant statistical progress in the drug’s safety and efficacy, with observed side effects such as decreased blood components and dizziness, requiring careful medical supervision. This step is part of Saudi Arabia’s initiatives to improve treatment options and enhance the efficiency of the healthcare sector in accordance with the Kingdom’s Vision 2030.
Notice: This Is an AI-Generated Summary
Comments (0)